This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrialfibrillation. Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). Circulation, Ahead of Print.
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with PreservedEjectionFraction (HFpEF).
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preservedejectionfraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.
The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preservedejectionfraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
55 
Let's personalize your content